These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 33431401)

  • 21. Association between Participation in Counseling and Retention in a Buprenorphine-Assisted Treatment Program for People Experiencing Homelessness with Opioid Use Disorder.
    Berry ARW; Finlayson TL; Mellis LM; Urada LA
    Int J Environ Res Public Health; 2021 Oct; 18(21):. PubMed ID: 34769591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prescribing of Opioid Analgesics and Buprenorphine for Opioid Use Disorder During the COVID-19 Pandemic.
    Currie JM; Schnell MK; Schwandt H; Zhang J
    JAMA Netw Open; 2021 Apr; 4(4):e216147. PubMed ID: 33856474
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patients Maintained on Buprenorphine for Opioid Use Disorder Should Continue Buprenorphine Through the Perioperative Period.
    Lembke A; Ottestad E; Schmiesing C
    Pain Med; 2019 Mar; 20(3):425-428. PubMed ID: 29452378
    [No Abstract]   [Full Text] [Related]  

  • 24. Low-Threshold Buprenorphine via Community Partnerships and Telemedicine-Case Reports of Expanding Access to Addiction Treatment During COVID-19.
    Levander XA; Wheelock H; Pope J; Lee A; Hartmann K; Abuelkhair S; Gregg JL; Buchheit BM
    J Addict Med; 2022 Jan-Feb 01; 16(1):e56-e58. PubMed ID: 34374502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expanding Access to Medications for Opioid Use Disorder: Federal Policy Is Only a Part of the Solution.
    Heidari O; Banta-Green CJ
    Am J Public Health; 2024 Jul; 114(7):693-695. PubMed ID: 38838294
    [No Abstract]   [Full Text] [Related]  

  • 26. Rapid upscale of depot buprenorphine (CAM2038) in custodial settings during the early COVID-19 pandemic in New South Wales, Australia.
    Roberts J; White B; Attalla D; Ward S; Dunlop AJ
    Addiction; 2021 Feb; 116(2):426-427. PubMed ID: 32888226
    [No Abstract]   [Full Text] [Related]  

  • 27. Trends in Buprenorphine Use in US Jails and Prisons From 2016 to 2021.
    Thakrar AP; Alexander GC; Saloner B
    JAMA Netw Open; 2021 Dec; 4(12):e2138807. PubMed ID: 34905010
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Availability and Opportunities for Expansion of Buprenorphine for the Treatment of Opioid Use Disorder.
    McKendrick G; Stull SW; Sharma A; Dunn KE
    Semin Neurol; 2024 Aug; 44(4):419-429. PubMed ID: 38876459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The COVID-19 pandemic and opioid use disorder: Expanding treatment with buprenorphine, and combining safety precautions with telehealth.
    Cales RH; Cales SC; Shreffler J; Huecker MR
    J Subst Abuse Treat; 2022 Feb; 133():108543. PubMed ID: 34210567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Buprenorphine in the United States: Motives for abuse, misuse, and diversion.
    Chilcoat HD; Amick HR; Sherwood MR; Dunn KE
    J Subst Abuse Treat; 2019 Sep; 104():148-157. PubMed ID: 31370979
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapid Access to Medications for Opioid Use Disorder.
    Kleinman RA; Morris NP
    J Gen Intern Med; 2021 Nov; 36(11):3557-3558. PubMed ID: 34047923
    [No Abstract]   [Full Text] [Related]  

  • 32. A national model of remote care for assessing and providing opioid agonist treatment during the COVID-19 pandemic: a report.
    Crowley D; Delargy I
    Harm Reduct J; 2020 Jul; 17(1):49. PubMed ID: 32680520
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Telemedicine Buprenorphine Clinic to Serve New York City: Initial Evaluation of the NYC Public Hospital System's Initiative to Expand Treatment Access During the COVID-19 Pandemic.
    Tofighi B; McNeely J; Walzer D; Fansiwala K; Demner A; Chaudhury CS; Subudhi I; Schatz D; Reed T; Krawczyk N
    J Addict Med; 2022 Jan-Feb 01; 16(1):e40-e43. PubMed ID: 33560696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Buprenorphine shared medical appointments for the treatment of opioid dependence in a homeless clinic.
    Doorley SL; Ho CJ; Echeverria E; Preston C; Ngo H; Kamal A; Cunningham CO
    Subst Abus; 2017; 38(1):26-30. PubMed ID: 27897918
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expanding access to buprenorphine treatment in rural areas with the use of telemedicine.
    Weintraub E; Greenblatt AD; Chang J; Himelhoch S; Welsh C
    Am J Addict; 2018 Dec; 27(8):612-617. PubMed ID: 30265425
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increasing Access to Buprenorphine in Safety-Net Primary Care Clinics: The New York City Buprenorphine Nurse Care Manager Initiative.
    Kaplan-Dobbs M; Kattan JA; Tuazon E; Jimenez C; Saleh S; Kunins HV
    Am J Public Health; 2021 Feb; 111(2):215-218. PubMed ID: 33351661
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medication-assisted therapy for opioid-dependent incarcerated populations in New Mexico: statewide efforts to increase access.
    Trigg BG; Dickman SL
    Subst Abus; 2012; 33(1):76-84. PubMed ID: 22263716
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medication Treatment of Adolescent Opioid Use Disorder in Primary Care.
    Carney BL; Hadland SE; Bagley SM
    Pediatr Rev; 2018 Jan; 39(1):43-45. PubMed ID: 29292291
    [No Abstract]   [Full Text] [Related]  

  • 39. A Primary Care Response to COVID-19 for Patients with an Opioid Use Disorder.
    Wilson CG; Ramage M; Fagan EB
    J Rural Health; 2021 Jan; 37(1):169-171. PubMed ID: 32277732
    [No Abstract]   [Full Text] [Related]  

  • 40. Opioid treatment programs, telemedicine and COVID-19: A scoping review.
    Chan B; Bougatsos C; Priest KC; McCarty D; Grusing S; Chou R
    Subst Abus; 2022; 43(1):539-546. PubMed ID: 34520702
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.